Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sickle cell kidney hope: common diabetes drug tested to save kidneys

NCT ID NCT07175051

Recruiting now Disease control Sponsor: University of Illinois at Chicago Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether empagliflozin, a drug already approved for kidney disease in diabetes, can slow kidney damage in people with sickle cell anemia. About 20 adults with sickle cell disease and early signs of kidney trouble will take the drug for 6 months. Researchers will measure changes in urine and kidney scans to see if the drug helps protect kidney function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALBUMINURIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Albuminuria proteinuria sickle cell disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALBUMINURIA SICKLE CELL ANEMIA (HBSS, OR HBSΒ-THALASSEMIA0)

Contacts and locations

Study contacts

  • Contact

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Illinois Chicago, Sickle Cell Center

    RECRUITING

    Chicago, Illinois, 60302, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.